Woodline Partners LP Has $2.63 Million Holdings in Alto Neuroscience, Inc. (NYSE:ANRO)

Woodline Partners LP increased its position in shares of Alto Neuroscience, Inc. (NYSE:ANRO - Free Report) by 397.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 621,976 shares of the company's stock after acquiring an additional 496,976 shares during the quarter. Woodline Partners LP owned about 2.31% of Alto Neuroscience worth $2,631,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Wells Fargo & Company MN boosted its stake in Alto Neuroscience by 40.0% during the 4th quarter. Wells Fargo & Company MN now owns 10,989 shares of the company's stock worth $46,000 after acquiring an additional 3,139 shares during the last quarter. Deutsche Bank AG boosted its stake in Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company's stock worth $64,000 after acquiring an additional 3,629 shares during the last quarter. Rhumbline Advisers boosted its stake in Alto Neuroscience by 24.4% during the 4th quarter. Rhumbline Advisers now owns 25,556 shares of the company's stock worth $108,000 after acquiring an additional 5,008 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Alto Neuroscience by 15.0% during the 4th quarter. Bank of New York Mellon Corp now owns 52,271 shares of the company's stock worth $221,000 after acquiring an additional 6,812 shares during the last quarter. Finally, Jane Street Group LLC boosted its stake in Alto Neuroscience by 72.0% during the 4th quarter. Jane Street Group LLC now owns 18,600 shares of the company's stock worth $79,000 after acquiring an additional 7,783 shares during the last quarter.

Alto Neuroscience Stock Down 0.9%

Shares of NYSE ANRO traded down $0.03 during midday trading on Friday, reaching $2.67. The company's stock had a trading volume of 23,285 shares, compared to its average volume of 384,189. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. Alto Neuroscience, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $17.55. The stock has a market capitalization of $72.15 million, a price-to-earnings ratio of -1.14 and a beta of 1.87. The stock has a 50 day simple moving average of $2.36 and a 200-day simple moving average of $3.36.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.06. Equities research analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on ANRO. Wedbush restated a "neutral" rating and set a $4.00 target price on shares of Alto Neuroscience in a report on Thursday, May 15th. William Blair restated an "outperform" rating on shares of Alto Neuroscience in a report on Friday, March 21st. Finally, HC Wainwright began coverage on shares of Alto Neuroscience in a report on Monday, April 7th. They set a "buy" rating and a $10.00 target price on the stock. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $15.40.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.